Fotadex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fotadex

Quick Facts

Property Description
Active Ingredients Dexamethasone (Corticosteroid), Tobramycin (Aminoglycoside antibiotic)
Form Ophthalmic suspension, Ophthalmic ointment
Pharmacological Class Anti-infective/Corticosteroid combination
Common Use Managing ocular inflammation and associated bacterial infection risk
Origin Synthetic (Glucocorticoid and Aminoglycoside derivative)

Fotadex is a prescription-only medicine defined as a fixed-dose combination drug intended for topical ophthalmic use. It belongs to the high-level pharmacological class of an Anti-infective/Corticosteroid combination, a pairing that provides a dual therapeutic approach. This classification indicates the medicine's role in simultaneously addressing inflammation and the presence of, or risk of, bacterial contamination. Dexamethasone and Tobramycin are the two principal active ingredients in this synthetic formulation.

Composition and Dual Active Ingredients

The entity incorporates the synthetic glucocorticoid Dexamethasone (the corticosteroid component) and Tobramycin (the aminoglycoside antibiotic component). Dexamethasone is clinically recognized for its potent anti-inflammatory effects, which makes it effective in reducing severe tissue reaction. The combination is explicitly recommended to treat certain steroid-responsive inflammatory ocular conditions when there is a risk of superficial bacterial ocular infection. This signifies that the medicine is designed to combat bacteria while concurrently reducing localized tissue reaction.

Dosage Forms and General Purpose

The product is supplied as a sterile preparation in two principal dosage form(s): a liquid Ophthalmic suspension and an Ophthalmic ointment. Both are specifically designed for the localized delivery of the actives directly onto the ocular surface, minimizing systemic exposure. The fundamental purpose of this formulation is to leverage the Dexamethasone for suppression of inflammatory response (reducing swelling and redness) and the Tobramycin component for targeted antimicrobial action as a bactericidal agent. This dual mechanism is particularly relevant in scenarios such as managing post-operative inflammation in the eye where concurrent infection risk must be controlled.

Regulatory References

  1. DailyMed Information

What side effects are possible with Fotadex?

Adverse Reaction Scope

The medicine's safety profile is defined by two primary risk categories: localized reactions from the antibiotic component (Tobramycin) and serious, duration-dependent risks from the steroid component (Dexamethasone).

Classification System-Organ Class Officially Documented Reactions
Common Eye Disorders Ocular hyperaemia (redness), eye pain, eye irritation, eyelid pruritus (itching)
Uncommon Nervous System, Eye Disorders Headache, eyelid oedema (swelling)
Not Known Eye Disorders Posterior subcapsular cataract, glaucoma, optic nerve damage, visual field defects

Serious Adverse Reactions and Safety Constraints

The regulatory label documents severe reactions associated mainly with the corticosteroid component. These include the potential for sustained elevation of intraocular pressure (IOP), which may lead to glaucoma and optic nerve damage with resulting visual field defects, and the formation of posterior subcapsular cataracts.

The steroid component is also officially stated to suppress the host response, increasing the risk of secondary ocular infections by non-susceptible organisms, particularly fungi. Use is restricted in the presence of certain viral, fungal, or mycobacterial eye infections. In cases of pre-existing corneal or scleral thinning disorders, the use of this medicine is associated with a risk of globe perforation.


Population and Duration Safety Notes

The risk of serious ocular effects like IOP elevation and cataract formation is explicitly linked to prolonged use (typically 10 days or longer). Due to this risk, official prescribing information notes that IOP should be routinely monitored during extended treatment.

Safety and effectiveness of this medicine have not been established in children under two years of age. For pregnant women, prolonged or repeated corticosteroid use has been associated with an increased risk of intra-uterine growth retardation, and systemic absorption risk to the infant is noted for use during lactation.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official regulatory information for Fotadex

Domain Official Regulatory Statement
Documented overdose presentations Acute localized overdose is characterized by an exacerbation of common adverse reactions, including punctate keratitis, erythema (redness), ocular edema (swelling), eyelid itching, and increased lacrimation (tearing).
Physiological systems affected (as stated in label) Ocular system; Endocrine system (potential for systemic steroid effects like Cushing's syndrome or adrenal suppression) following excessive use of the Dexamethasone component.
Dose-related or exposure-related factors (if applicable) Systemic effects are associated with the use of the corticosteroid component in excess of the listed dosing instructions or over prolonged periods.
Population-specific overdose notes (if applicable) Children and patients receiving concomitant treatment with CYP3A4 inhibitors are noted to be predisposed to the systemic effects (Cushing's syndrome/adrenal suppression) if the Dexamethasone component is used excessively.
Emergency-response statements (as written in official documents) Flushing of the eye(s) with lukewarm water is the described measure for acute, localized overdose in the eye(s). Treatment should be symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only) Seeking emergency medical attention or calling a Poison Help line is required if the product is accidentally swallowed (ingested).

Overdose Classifications (high-level)

Classification Aspect Regulatory Statement
Severity classification (as defined in official documents) Localized acute overdose is often classified by an intensification of local toxicity; severe outcomes are tied to systemic absorption from excessive chronic use rather than a typical acute systemic overdose.
Regulatory basis (EMA / FDA / etc.) Information derived from governmental and regulatory prescribing documents.
Overdose-context constraints (as defined in official documents) The profile emphasizes the distinction between local ocular overdose requiring flushing and accidental ingestion requiring immediate medical attention.

Resulting overdose structure

Official overdose statements:

  • Acute localized overdose may present with signs such as punctate keratitis, erythema, and ocular edema, which are manifestations of local ocular toxicity.
  • Accidental ingestion of the product requires the individual to seek emergency medical attention or call a Poison Help line.
  • Management of an ocular overdose involves the procedural action of flushing the affected eye(s) with lukewarm water.
  • The overall treatment approach for overdose is defined as symptomatic and supportive, and no specific antidote is known.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile primarily by differentiating between the relatively minor, localized ocular manifestations resulting from topical excess and the critical need to seek immediate medical attention following the highly improbable event of accidental ingestion of the product. The potential for severe outcomes, such as adrenal suppression, is documented as a systemic risk tied to the use of the corticosteroid component in excess of the listed dosing instructions, which is noted to be a particular concern for children.

Therapeutic Uses of Fotadex

Fotadex is a prescription combination medication used in specific ophthalmic contexts to address the dual therapeutic need for strong anti-inflammatory action and management of bacterial infection risk in the eye. It is primarily relevant when conditions characterized by periods of heightened symptoms (inflammation) are present and there is a simultaneous need to manage a superficial bacterial ocular infection or the risk of bacterial contamination.

The medicine is used for steroid-responsive inflammatory ocular conditions, which may include certain forms of keratitis, conjunctivitis, and blepharitis, and is relevant in clinical settings that involve acute or disruptive symptom patterns.

“This approach assists with maintaining functional stability and supports the patient during difficult episodes by easing distress related to post-operative tissue reaction.”

In clinical settings, this medication is often applied during phases when symptoms become more noticeable following procedures like cataract extraction or in scenarios requiring short-term symptomatic assistance. It plays a role in managing symptoms that interfere with daily comfort while assisting in addressing the bacterial component.


Quick Fact: Support for Ocular Discomfort

Fotadex is commonly used to help with symptom clusters that may become intense or disruptive, such as redness, swelling (edema), and pain. This application contributes to improved comfort during symptomatic periods.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Fotadex — Official Regulatory Information

The eligibility for using Fotadex is strictly defined by regulatory criteria regarding a patient’s medical status and age. The medicine is contraindicated and must not be used by individuals with certain ocular infections, including Epithelial Herpes Simplex Keratitis, Vaccinia, Varicella, and other viral, fungal, or mycobacterial diseases of the eye. Use is also prohibited for individuals with a documented hypersensitivity to the active ingredients (Tobramycin, Dexamethasone) or any components of the formulation.


Age-Based and Special Population Rules

Fotadex is approved for use in adults and pediatric patients aged 2 years and older. Safety and effectiveness have not been established in children under the age of 2 years. No overall differences in safety or effectiveness have been noted for older (geriatric) patients.


Condition-Based Restrictions

Patients with pre-existing conditions such as Glaucoma must use the medicine with caution, and their intraocular pressure (IOP) must be routinely monitored during treatment. Caution is also required in individuals with thinning of the cornea or sclera.

For pregnancy, use is permitted only if the potential benefit justifies the potential risk to the fetus, and caution should be exercised during lactation.

What should I know about interactions with other medicines?

The official regulatory profile for Fotadex (Dexamethasone and Tobramycin ophthalmic suspension/ointment) documents a specific interaction constraint related to co-administration with other anti-infective agents. Due to the medicine's topical administration, the interaction map is highly defined, with minimal documented systemic pharmacokinetic interactions.

The single, officially recognized drug-drug interaction involves Systemic Aminoglycoside Antibiotics. The topical Tobramycin component, when used alongside systemic medicines from the same aminoglycoside class, creates the potential for additive systemic exposure and associated toxicity risk. This combination is not formally prohibited; however, the regulatory constraint dictates a required procedural action: the total serum concentration of the systemic aminoglycoside must be monitored. This requirement is the principal, documented interaction-related restriction for the medicine.

No specific interactions are documented in the official prescribing information regarding common metabolic pathways, such as CYP enzymes or drug transporters. Furthermore, regulatory labels do not specify any mandatory time-separation rules for administration with other medicines. Interactions with food, alcohol, herbal products, or dietary supplements are also not documented in the official profile for this ophthalmic formulation. The overall structure of the interaction information is thus limited to the constraint on combined systemic and topical aminoglycoside use.

Mechanism of Action

How Fotadex Works

Fotadex is a fixed-dose combination that exerts influence over two distinct biological systems: host inflammation and microbial viability. Its mechanism operates strictly at the molecular and cellular levels.


1. Genomic Suppression of Pro-Inflammatory Signaling

This domain explains how the Dexamethasone component acts as an agonist for the Intracellular Glucocorticoid Receptor ( GR), leading to transrepression of pro-inflammatory genes. This molecular cascade results in the suppression of the synthesis and release of inflammatory mediators (like prostaglandins and cytokines), contributing to a shift in fluid dynamics and leukocyte motility—key physiological consequences of inflammation.


2. Irreversible Disruption of Bacterial Protein Synthesis

This domain covers the bactericidal action of the Tobramycin component. It works by binding irreversibly to the bacterial 30S ribosomal subunit, which causes a severe misreading of the mRNA template. The resulting accumulation of defective, non-functional proteins rapidly leads to a profound disruption of cellular integrity, which is the physiological action that results in the loss of microbial viability.

Dosage and Administration Information

Official Administration Guidelines for Fotadex

Fotadex ophthalmic suspension must be administered topically into the conjunctival sac(s) of the affected eye(s) only. This product is a suspension and must be shaken well before each use to ensure proper content distribution.


Dosing Schedule and Frequency

Administration Detail Official Regulatory Rule
Route of Administration Ocular (into the conjunctival sac(s))
Standard Dosing Instill one drop every four to six hours.
Initial Intensified Dosing During the initial 24 to 48 hours, the dosage may be increased to one drop every two hours.
Therapy Adjustment Frequency must be decreased gradually as warranted by improvement in clinical signs.

Procedural Requirements

Care should be taken not to discontinue therapy prematurely. The initial prescription and any renewal of the medication order should be made by a physician only after an examination of the patient using magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. The total quantity prescribed initially should generally not exceed 20 mL, and the prescription should not be refilled without further patient evaluation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fotadex

The research available for Fotadex, which combines the corticosteroid dexamethasone and the antibiotic tobramycin, explores the drug's properties in specific eye conditions. The evidence used by regulatory bodies typically involves studies that compare the combination to other active treatments or research that demonstrates formulation consistency.


Evidence for Steroid-Responsive Ocular Inflammation and Infection Risk

The research base consists of short-term Randomized Controlled Trials (RCTs) and studies designed to measure whether different versions of the drug are equivalent (bioequivalence). Research has explored how symptoms and signs change over time in patients with conditions characterized by periods of heightened symptoms, in scenarios that include a co-existing need to address bacterial contamination.

These studies monitored physical and subjective outcomes, including changes in objective clinical signs of inflammation and patient-reported outcomes describing perceived discomfort. Findings describe group patterns that were observed in the studies, detailing the measured changes in these outcomes over the defined short follow-up period. Research highlights changes measured during the study period, but the evidence remains limited regarding the long-term outcomes for patients. Few data are available for what patterns were observed regarding the recurrence of these inflammatory conditions over extended periods.


Research Focus on Post-operative Inflammation (Cataract Surgery)

This research area was studied for its relevance following procedures such as cataract extraction. The studies primarily examined the use of the steroid component (dexamethasone) within various regimens, evaluating its role in settings involving inflammation in the immediate post-operative period.

Research examined outcomes linked to inflammatory or irritative states, focusing on measurable signs of internal eye inflammation and monitoring changes in the eye’s internal pressure (IOP). The findings primarily reflect temporary physiological imbalance and cover the acute recovery phase, typically observed over a short-term to intermediate follow-up duration. Evidence contributes to understanding symptom patterns. Research specifically on this fixed combination, as opposed to the steroid used alone, constitutes only part of the evidence base in this setting.

Key Studies & References

  1. Dexamethasone and Tobramycin Ophthalmic Suspension DailyMed Information (NIH/NLM)
  2. A Clinical Study to Compare Loteprednol/Tobramycin Ophthalmic Suspension to Dexamethasone/Tobramycin Ophthalmic Suspension in Subjects With Blepharoconjunctivitis (NCT03975374) - Clinical Trial Registry
  3. A Clinical Study Comparing Dexamethasone-Tobramycin Ophthalmic Suspension With Gatifloxacin Ophthalmic Solution in Patients With Acute Blepharokeratoconjunctivitis (NCT01028027) - Clinical Trial Registry

Frequently Asked Questions (FAQ)

Common questions about Fotadex (FAQ)

Q: Does Fotadex interact with common pain relievers like ibuprofen or acetaminophen?

A: Official regulatory documents do not list specific interactions between Fotadex and common, non-prescription pain relievers or anti-inflammatories. The primary documented drug-drug interaction is with systemic aminoglycoside antibiotics. Information regarding all medicines being taken is relevant for a prescribing healthcare provider.

Q: What happens if I miss a dose of Fotadex?

A: Official patient instructions typically state that a missed dose should be applied or instilled as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is continued. Regulatory guidance advises against using extra medication to compensate for a missed dose.

Q: Can children use Fotadex, and is the dosage the same as for adults?

A: Official regulatory information confirms that Fotadex is approved for use in pediatric patients aged two years and older. The dosage and administration schedule for pediatric patients must be determined by the prescriber, as the standard adult dosing schedule is not automatically suitable for all children.

Q: What is the proper technique for applying Fotadex eye drops?

A: The medicine is directed to be administered topically into the conjunctival sac only. The full, detailed technique for application, including proper hand hygiene and avoiding contamination of the dropper tip, is provided in the official patient instructions.

Q: Is it true that prolonged use of Fotadex can affect vision?

A: Yes, official warnings indicate that prolonged use of the corticosteroid component may lead to serious ocular effects. These include the formation of posterior subcapsular cataracts (clouding of the eye lens) and a potential increase in intraocular pressure (IOP), which can result in glaucoma and damage to the optic nerve. The official warnings regarding these risks are the basis for the physician's decision regarding the appropriate, typically limited, duration of treatment.

Q: Can Fotadex be used for non-eye conditions?

A: No. According to the official product labeling, Fotadex is indicated and formulated for topical ophthalmic use only. This means it is designed to be applied directly to the eye and surrounding areas and is not intended for use in other parts of the body.

Q: Is it okay to wear contact lenses while using Fotadex?

A: Official warnings state that soft contact lenses should generally not be worn while using this product. The preservative contained in the suspension, Benzalkonium Chloride, may be absorbed by the soft lenses. A healthcare provider must determine when it is safe to resume wearing contact lenses.

Q: Do I need a prescription to get Fotadex, or is it over-the-counter?

A: Fotadex is classified as a prescription-only drug. It is not available as an over-the-counter (OTC) medication due to the combination of a corticosteroid and an antibiotic.

Q: How long can I safely use Fotadex before needing a break?

A: The duration of use is determined by the prescribing physician. The regulatory label explicitly notes that the risk of elevated intraocular pressure (IOP) is linked to using the medication for 10 days or longer, necessitating routine IOP monitoring during extended treatment.

Q: Is a slight stinging sensation normal right after applying Fotadex?

A: The official documentation lists certain localized reactions as frequent adverse effects, which can include ocular irritation, eye pain, and itching. A stinging sensation upon application can be part of this expected local irritation, but any severe or persistent discomfort is a relevant matter to discuss with a healthcare professional.

Q: Are there any specific foods or drinks to avoid while using Fotadex?

A: Regulatory documents do not specify any mandatory changes to diet while using Fotadex. There are no documented interactions with food or alcohol in the official prescribing information for this topical ophthalmic formulation.

Q: Can Fotadex cause temporary blurred vision?

A: Yes, regulatory documentation states that vision may be temporarily blurred immediately following the application of the ophthalmic suspension or ointment. This effect is generally mild and short-lived.

Q: Where should I store Fotadex once I open it?

A: The ophthalmic suspension must be stored upright within the specified temperature range, away from freezing. Importantly, once the bottle is opened, it must generally be discarded after four weeks to maintain sterility and efficacy.

Q: Does using Fotadex affect my ability to drive or operate machinery?

A: Because temporary blurred vision is a documented side effect, official guidance notes that patients should exercise caution regarding driving or operating machinery after application until vision is clear.

Q: Is Fotadex safe to use during pregnancy or while breastfeeding?

A: In pregnancy, the product should be used only if the potential benefit is determined to justify the potential risk to the fetus, as prolonged corticosteroid use has been linked to potential growth issues. Caution should be exercised during lactation, as it is unknown if the components are absorbed systemically enough to be found in breast milk.

Q: Why is shaking the bottle sometimes recommended for certain eye drops like Fotadex?

A: Fotadex is a liquid suspension, meaning the active ingredients are mixed but not dissolved. It must be shaken well before each use to ensure the active components are evenly distributed, helping to ensure that the proper concentration of active ingredients is delivered in every drop.

Q: What is the average shelf life of Fotadex once the bottle is opened?

A: To maintain sterility and effectiveness, the ophthalmic suspension must generally be discarded four weeks after first opening, regardless of how much medication remains in the bottle.

Q: Does Fotadex interact with blood thinners or diabetes medication?

A: The official regulatory label does not document specific drug interactions between Fotadex and blood thinners (anticoagulants) or diabetes medications. The principal documented concern involves co-administration with systemic aminoglycoside antibiotics.

Q: What does the combination of ingredients in Fotadex achieve?

A: The combination is designed to provide a dual therapeutic approach. The corticosteroid component (Dexamethasone) suppresses severe ocular inflammation, while the antibiotic component (Tobramycin) provides targeted antimicrobial action to address existing or potential superficial bacterial ocular infection.

Q: Can older adults use Fotadex without increased risk?

A: Official regulatory data indicate that no overall differences in safety or effectiveness have been noted between older (geriatric) patients and younger adult patients. The label specifically mentions this data point regarding the use of the medication in this population.

Q: Does Fotadex have a 'rebound' effect if I stop using it suddenly?

A: The official administration guidelines advise that the frequency of application should be decreased gradually as the patient's condition improves, and care should be taken not to discontinue therapy prematurely. This procedural guidance supports the management of the treated condition.

Q: Is the preservative in Fotadex known to cause irritation for some people?

A: The formulation contains the common preservative benzalkonium chloride. The FDA notes its potential to be absorbed by soft contact lenses. Patients with known sensitivities to preservatives should ensure their prescriber is aware of this concern.

Q: Can Fotadex be used for chronic, long-term eye conditions?

A: The regulatory label explicitly links the risk of serious ocular effects, like glaucoma and cataracts, to prolonged use of the corticosteroid component (typically 10 days or longer). The determination of suitability for chronic conditions, which often require extended treatment, must be made by a healthcare provider, given the risks associated with prolonged use.

Q: What are the non-active ingredients in Fotadex?

A: The non-active ingredients, or excipients, are listed in the official description section of the product labeling. These components typically include a preservative (such as Benzalkonium Chloride), sodium chloride, tyloxapol, and various agents used to adjust the pH level to ensure the suspension is stable and safe for the eye.

Q: How long does the effect of one application of Fotadex typically last?

A: While the exact duration of the therapeutic effect is not precisely quantified, the standard dosing regimen is structured around a typical interval of one drop every four to six hours. This interval provides an indication of the expected period between necessary applications.

How should Fotadex be stored and disposed of?

How to Store and Dispose of Fotadex

Fotadex (tobramycin and dexamethasone ophthalmic product) must be stored according to specific regulatory requirements to maintain its sterility and efficacy.


Mandatory Storage Conditions

Formulation Required Temperature Range Handling/Protection Rule
Ophthalmic Ointment 2 C to 25 C (36 F to 77 F) Keep container tightly closed
Ophthalmic Suspension 8 C to 27 C (46 F to 80 F) Shake well before use; Do not freeze

Stability and Disposal

The ophthalmic suspension must be stored upright and generally must be discarded four weeks after first opening. The container tip must not be touched to prevent contamination of the sterile product. As a general rule for all medicines, the product should be kept out of the reach of children. Unused or expired Fotadex must be disposed of in accordance with local regulations for pharmaceutical waste, as specific household disposal instructions are not typically provided in the primary labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fotadex found in:

A-Z Index: